Hangzhou tengdi biological (20n bio), a new AI aided protein design company, completed a seed round financing of US $3.3 million

On December 17, 2021, Hangzhou tengdi biology Co., Ltd., which focuses on AI aided design of new protein drugs (20n bio, hereinafter referred to as tengdi Biology) announced the completion of a seed round financing of US $3.3 million. This round of financing is led by venture capital firm LanChi venture capital. The company will use this financing to expand its professional team, establish a strong protein drug design and screening platform, and layout the early concept verification of multiple tumor and other genetic disease pipelines. Tengdi biology was registered and established in Hangzhou at the end of September 2021, and its R & D center is located in Philadelphia, USA, where biomedical scientific and technological talents gather. Dr. Zhu Mingqu, the founder, was an assistant professor of bioinformatics at Duke University School of medicine in the United States. Later, he held senior management positions in many leading biotechnology companies in the United States and China, and founded many AI enabled biotechnology companies. Only two months after its establishment, tengdi biology quickly established a full-time staff team composed of five doctors from famous universities at home and abroad, with an average working experience of nearly 20 years after graduation. Dr. Chen Xiaole, director and R & D director of the company, once served as the deputy director of antibody engineering of novalock, an American subsidiary of Shijiazhuang Pharmaceutical Group, and has rich experience in antibody drug development. Tengdi biology is still actively expanding its team. The company has invited Dr. Zhou Yaoqi, a famous structural biologist, protein design expert, Dr. Cao Longxing, a "35 scientific and technological innovators under the age of 35" in the Asia Pacific region of MIT science and technology review, and many other well-known professors to serve as the company's scientific consultants.